It's been nothing but 100% improvement.It just continues to get better.Ive been avoiding doing stairways and I have to be real careful climbing in and out of equipment. I find myself being a lot more relaxed, not having the problems, not having the pain. I don't have the swelling in my knees that I used to have and it hasnt been waking me up at night. View my video testimonial here My name is Susan and Im 62 year old I just finished having my second PRP treatment and Im very, very happy with the results I can do all kinds of things I wasn't able to do beforeI believe my knee will continue to get better as the cartilage grows. Thank you! View my video testimonial here Many thanks to the Stem MD team for giving me the use of my hands back, pain free! Professional, courteous and compassionate, describes this team of caring people. To anyone considering this procedure, I say you will be amazed and thankful at the results. Lenita Brewer Ansonia, Ohio Thank you for giving my life and health back. The PRP treatment worked wonders and helped alleviate the pain. I highly recommend the anti-inflammatory … Continue reading →

NIBSC/SCIENCE PHOTO LIBRARY Embryonic stem cells may have the ability to repair damaged tissue. A landmark stem-cell trial is sputtering back to life two-and-a-half years after it was abandoned by the California company that started it. But it now faces a fresh set of challenges, including a field that is packed with competitors. The trial aims to test whether cells derived from human embryonic stem cells can help nerves to regrow in cases of spinal-cord injury. It was stopped abruptly in 2011 by Geron of Menlo Park, California (see Nature 479, 459; 2011); the firm said at the time that it wanted to focus on several promising cancer treatments instead. Now, a new company Asterias Biotherapeutics, also of Menlo Park plans to resurrect the trial with a US$14.3-million grant that it received on 29May from the California Institute for Regenerative Medicine (CIRM), the states stem-cell-funding agency. But the field has moved on since Geron treated its first patient in 2010, and the therapy that Asterias inherited is no longer the only possibility for spinal-cord injury. StemCells, a biotechnology company in Newark, California, has treated 12 patients in a safety study of a different type of stem cell, and it plans … Continue reading →

Boston, MA (PRWEB) June 03, 2014 Today, Dr. James L. Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC) described a new technology for identification of new drug candidates that are toxic to adult stem cell cells in the human body. The new AlphaSTEM technology is the first of its kind to address a long-standing unmet need in the pharmaceutical industry. Dr. Sherley presented the AlphaSTEM technology at the 7th Annual Massachusetts Life Sciences Innovation Day (MALSI Day 2014; http://www.mattcenter.org/malsi-day-2014/home.html) at the Harvard Club of Boston. ASCTC is one of a select number of start-up companies invited to present posters on their newest innovative biotechnologies at the all day event, which features the best and brightest life sciences innovations of the year. Just as adult stem cells are crucial for life and normal organ function, their safety is crucial for successful treatment with new drugs. Even if a new drug has high activity against a disease or disorder; it will not be an effective treatment, if it is also too toxic to adult stem cells. Adult stem cells are found in all renewing tissues and organs of the human body, like hair, skin, liver, and even the … Continue reading →

Dr. Mark Penn, founder and CMO of Juventas Therapeutics While the optimal treatment for heart failure was provided to a group of patients, they were still having symptoms. However when a new drug therapy based in regenerative medicine was given to these patients they showed clinically meaningful improvements in end systolic volumes, end diastolic volumes, ejection fraction and NTproBNP levels. The drug, produced by Cleveland, Ohio-based Juventas Therapeutics, called JVS-100, is a non-viral gene therapy that expresses SDF-1 and promotes endogenous stem cell repair of the heart in patients with severe heart failure. "What was remarkable about the improvement is that this drug was given to patients who had heart failures stemming from heart attacks that occurred - on average- about eleven years ago," said Dr. Mark Penn, founder and CMO of Juventas Therapeutics, and director of Cardiovascular Research at Summa Health System in Akron, Ohio. Penn presented phase II clinical data last month at the European Society of Cardiology- Heart Failure Congress in Athens, Greece. The field of regenerative medicine, which is the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function, has come a long way. Penn explained that 14 … Continue reading →